This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Quest Diagnostics (DGX) Stock Gains on EUA for Monkeypox Test
by Zacks Equity Research
According to Quest Diagnostics (DGX), this test can differentiate monkeypox viral DNA from other non-variola orthopoxviruses in a specimen, helping to enable a faster final diagnosis.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Edward Lifesciences (EW) Gains From New Products Amid Cost Woe
by Zacks Equity Research
Edwards Lifesciences (EW) expects full-year 2022 underlying sales to grow on the back of strength in demand for products used in more intense surgeries.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Boston Scientific's (BSX) WATCHMAN FLX to Offer DAPT in the US
by Zacks Equity Research
Boston Scientific (BSX) to offer updated labeling for WATCHMAN FLX device after receiving FDA approval.
Here's Why You Should Hold on to Allscripts (MDRX) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
HealthEquity (HQY) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in majority of its segments, in the second quarter of fiscal 2023.
Zacks.com featured highlights include Marubeni, AMN Healthcare Services, Veritiv and Universal Logistics Holdings
by Zacks Equity Research
Marubeni, AMN Healthcare Services, Veritiv and Universal Logistics Holdings are part of Zacks Screen of the Week article.
Factors that Make Humana (HUM) an Attractive Bet Now
by Zacks Equity Research
Humana (HUM) continues to gain on continued top-line growth resulting from its solid Medicaid and Medicare businesses. A strong cash position enables HUM to undertake growth-related investments.
SmileDirectClub (SDC) Faces Low Aligner Shipment, Margin Woe
by Zacks Equity Research
The ongoing macroeconomic challenges continue to impact SmileDirectClub's (SDC) core demographic and business spending.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.
CVS Health (CVS) to Buy Signify Health, Grow in Home Healthcare
by Zacks Equity Research
According to CVS Health (CVS), Signify Health, as a leading healthcare platform, will play a critical role in advancing the company's healthcare services strategy.
Baxter (BAX) Novum IQ SYR's FDA Clearance Boosts Patient Care
by Zacks Equity Research
Latest regulatory approval for Baxter's (BAX) Novum IQ SYR is expected to provide safe and accurate infusions for vulnerable patients.
Here's Why You Should Hold on to BD (BDX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.
Scoop Up Big Gains With 4 Stocks Witnessing Rise in Cash Flow
by Moumita C. Chattopadhyay
Cash is the lifeblood of any business and provides strength to a company and so MARUY, AMN, VRTV and ULH are worth buying.
Zacks.com featured highlights include Industrias Bachoco S.A.B. de C.V., AMN Healthcare, Veritiv and CONSOL Energy
by Zacks Equity Research
Industrias Bachoco S.A.B. de C.V., AMN Healthcare, Veritiv and CONSOL Energy are part of Zacks Screen of the Week article.
Humana (HUM) Brings Home Health Unit of KAH Under CenterWell
by Zacks Equity Research
Humana (HUM) wraps up rebranding KAH's home health operations to the CenterWell brand. This leads to the clubbing of HUM's three payer-agnostic care services into a common suite.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) segmental results and robust bookings and backlog growth.
Zimmer Biomet (ZBH) Signs Co-Marketing Agreement for HipInsight
by Zacks Equity Research
Zimmer Biomet's (ZBH) HipInsight is a mixed reality-based visualization tool that will aid surgeons in precise implant placement and alignment during total hip replacement.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.
Masimo's (MASI) Latest Watch to Improve Patient Outcomes
by Zacks Equity Research
Masimo's (MASI) full-market consumer release of the Masimo W1 and other related launches is likely to significantly improve RPM.
Chemed's (CHE) Roto-Rooter Growth Aids, Macro Challenges Ail
by Zacks Equity Research
Chemed's (CHE) VITAS segment revenue decline during the second quarter gets somewhat offset by a geographically weighted average Medicare reimbursement rate increase of nearly 1.3%.
Here's Why You Should Retain Haemonetics (HAE) Stock Now
by Zacks Equity Research
Investors are optimistic about Haemonetics' (HAE) better-than-expected results and strong Plasma sales.
Haemonetics (HAE) Business Recovery Continues, Macro Issues Ail
by Zacks Equity Research
Despite sluggish results of Haemonetics' (HAE) Blood Center business, Whole Blood revenues grow on favorable order timing among distributors in the Asia Pacific and EMEA.
Nevro's (NVRO) PDN Therapy Gets Positive Coverage Updates
by Zacks Equity Research
Latest favorable coverage decisions for Nevro's (NVRO) PDN Therapy are expected to serve a wider patient pool.